Neurocrine Biosciences

AbbVie

Gilead Sciences

BioMarin Pharmaceutical

United Therapeutics

Sarepta Therapeutics

Amgen

Incyte

Natera

Alnylam Pharmaceuticals

SPDR S&P Biotech ETF

XBI tracks an equal-weighted index of US biotechnology stocks.

Capricor Therapeutics

Mesoblast

Stem-cell research is on the cusp of a breakthrough that could come as soon as 2025, and two biotech companies with promising therapies stand to gain, according to a new report from Maxim Group on Thursday.

RFK Jr. could prove a surprise boon for stem-cell stocks with pivotal year ahead

Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.

Should You Invest in the SPDR S&P Biotech ETF (XBI)?

Investing in biotech offers high upside but comes with significant risks, especially with volatile stock movements and binary outcomes from clinical trials, says Jonathan Faison. Focus on multi-year clinical and commercial momentum, diversifying with multiple drug candidates.

Finding Winners In Biotech, Probably The Riskiest Sector

iShares Nasdaq Biotechnology ETF

The biotech sector recently experienced a sharp reversal following a failed breakout attempt post-election. While most areas of the market surged to new heights after Donald Trump's election win on November 5, biotech ETFs like the iShares Biotechnology ETF NASDAQ: IBB and the SPDR Biotech ETF NYSE: XBI stopped short of new 52-week highs.

Is Biotech's Bull Run Over? Examining Election Impacts

Biotech had its worst weekly performance since 2020 last week, driven by the post-election rally fizzling and fears surrounding RFK Jr.'s potential impact on the FDA. Concerns about Mr. Kennedy leading the HHS are likely overblown; his confirmation is uncertain, and his focus may impact the food sector more than biotech. The biotech sector appears oversold with little “froth,” especially compared to the overall market, suggesting a buying opportunity for long-term investors.

Biotech: 3 Reasons The Recent Selloff Is A Buying Opportunity For XBI (Upgrade)

iShares U.S. Digital Infrastructure and Real Estate ETF

First Trust Indxx Aerospace & Defense ETF

First Trust NASDAQ-100 Technology Sector Index Fund

SPDR S&P Semiconductor ETF

Investors can take advantage of beaten-down prices because the second Trump administration is likely to boost stocks.

5 Top-Ranked ETFs to Buy on the Dip

Moderna

Novo Nordisk

Pfizer

With Trump's appointment of Robert F. Kennedy Jr. as the secretary of Health and Human Services, the biotech industry has more questions than answers.

Trump Taps RFK for HHS: Time to Avoid Biotech?

Biotech stocks jumped early Wednesday on hopes for more innovation and dealmaking after Donald Trump clinched his second presidency. The post Biotech Stocks Edge Higher.

Biotech Stocks Edge Higher. Could Trump 2.0 Mean More Innovation, Dealmaking?

ARK Genomic Revolution Multi-Sector ETF

First Trust Health Care AlphaDEX Fund

iShares Global Healthcare ETF

Vanguard Health Care ETF

Health Care Select Sector SPDR Fund

The best healthcare ETFs patch investors into an area of the market that offers both defensive properties and long-term growth.

Best Healthcare ETFs To Buy Now

A smart beta exchange traded fund, the SPDR S&P Biotech ETF (XBI) debuted on 01/31/2006, and offers broad exposure to the Health Care ETFs category of the market.

Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?

SPDR® S&P Biotech ETF is a well-diversified, low-cost ETF that can be an excellent tool to capitalize on the potential of the biotech stock sector. XBI's performance should be compared with the Russell 2000, not the S&P 500, due to its heavy focus on small- and mid-cap stocks. I believe that economic conditions are favorable for growth in the biotechnology sector, despite the recent spike in over 20-year Treasury bond yields.

XBI: Biotech ETF Is A Must Have

Exelixis

Amicus Therapeutics

Merck

Teva Pharmaceutical

The small cap biotech sector is trading close to the same levels that it was five years ago. Straight equity holdings have threaded water in this space over the past half decade. However, given the lucrative option premiums available against many names in this area, a covered call strategy has worked quite successfully for my portfolio on a consistent basis.

3 Attractive Biotechs With Recent Positives

Dynavax Technologies

GlaxoSmithKline

Intellia Therapeutics

Small-cap biotech stocks have struggled over the past five years, but lower interest rates may boost sentiment and M&A activity, benefiting the sector. One way I have kept my biotech portfolio churning out profits is by embracing using covered call orders to establish positions in small-cap biotech names. Many of these have become consistent profitable “rinse, wash and repeat” trades over the years.

3 'Repeatable' Biotech Trades

As a new regime and phase begin for the market and economy, after the FED cut interest rates by a surprising 50bps last Wednesday, several new opportunities and sector bull and bear markets might begin.

Biotech Boom Ahead? Key Stocks and ETFs to Watch Now

Biotechnology equities have underperformed since late 2020, but recent acquisitions and drug approvals suggest a potential industry revaluation. SPDR S&P Biotech ETF (XBI) offers broad exposure to the biotech sector, with equal weighting reducing susceptibility to individual stock movements. XBI shows strong support around $96 and $90, with the potential to break resistance at $102.50, especially if the Federal Reserve cuts rates.

XBI Is Breaking Out And Likely To Outperform In The Near Term (Technical Analysis)

Thanks to the prospect of lower interest rates, shares of biotech companies have doubled the gains of the broad market over the past few months.

Biotech Stocks Are Showing Signs of Life. Why the Rally Could Continue.

Stock valuations in the pharmaceutical industry are becoming more attractive for potential mergers due to declining IPO prices. Aging population and prevalence of chronic diseases are driving favorable prospects for the drug industry.

Biopharmaceutical Stocks: The Next Phase Of The Rally Appears To Be Underway

iShares Core U.S. Aggregate Bond ETF

YieldMax COIN Option Income Strategy ETF

Calamos S&P 500 Structured Alt Protection ETF-August

Invesco DB Agriculture Fund

Eaton Vance Floating-Rate ETF

VanEck Junior Gold Miners ETF

iShares iBoxx High Yield Corporate Bond ETF

iShares iBoxx $ Investment Grade Corporate Bond ETF

iShares MSCI Global Gold Miners ETF

Amplify Junior Silver Miners ETF

 SPDR Blackstone Senior Loan ETF

iShares 20+ Year Treasury Bond ETF

Yieldmax Tsla Option Income Etf

United States Natural Gas Fund LP

Global X Uranium ETF

Hello! Bonds seemed more appealing to ETF investors than ever before in July, based on flow data from State Street. This week's ETF Wrap looks at what's driving investors' appetite for fixed income lately, and where their money flowed within fixed income.

Bond ETFs attract record flows in July as investors position for Fed rate cuts

Biotech indexes lagged broader market indexes in the first half of 2024, and trade at the same level as in early 2022. Biotech valuations are closely tied to the Fed's interest rate policy and are highly correlated to the 10-year yield. Inflation is likely to trend lower, and, along with rising unemployment, should persuade the Fed to cut rates this year in September.

Biotech Stocks 2024 Second Half Outlook - Buy Biotechs

Bristol-Myers

Ionis Pharma

Mergers and acquisitions are on pace for a solid year. Small-cap biotech and tech look interesting.

M&A Is Back. 4 Stocks That Could Be Targets.

One of our favorite parts of rolling into a new month at Schaeffer's is digging into seasonality and historic trends of stocks, sectors, and exchange traded funds (ETFs).

Outperforming ETF Could Keep Rallying in June

Altimmune

Structure Therapeutics Inc

Undervalued biotech stocks can offer some of the most explosive opportunities. That is, if you can spot the right one at the right time.

The 3 Most Undervalued Biotech Stocks to Buy in June 2024

Principal Healthcare Innovators Index ETF

Fidelity MSCI Health Care ETF

Amplify Treatments Testing & Advancements ETF

Global X Health Care Covered Call & Growth ETF

SPDR S&P Insurance ETF

Direxion Daily Pharmaceutical & Medical Bull 3X Shares

Invesco DWA Healthcare Momentum ETF

Invesco S&P 500 Equal Weight Health Care ETF

SPDR Portfolio S&P 500 Growth ETF

SPDR Portfolio S&P 500 Value ETF

Amplify Weight Loss Drug & Treatment ETF

SPDR S&P Health Care Equipment ETF

SPDR S&P Health Care Services ETF

SPDR S&P Pharmaceuticals ETF

Sometimes it feels like it's Nvidia's world and we all just live in it. Why bother with anything else?

Finding Opportunity in Unloved Healthcare ETFs

Innovation has been a hallmark of biotechnology for decades and, despite some of the hardest sledding in many years, 2024 could be a bounce-back year for biotech stocks. The sector has suffered in this cycle.

Why the Rest of 2024 Could Be Good for Investing in Biotech Stocks

Biotech indexes, represented by IBB and XBI, have been facing pressure since March and trading at valuations seen in April 2020. The key factor influencing biotech valuations, discussed below, is expected to become more favorable in the second half as rate-cut uncertainty diminishes. While biotechs have significantly lagged behind the broader market, there is reason to be optimistic once inflation-related volatility subsides. IBB and XBI present good vehicles for biotech exposure.

News for SPDR S&P Biotech ETF ETF (XBI)